In Cancer, Boosting Chemotherapy while Reducing Toxic Side Effects is a Potential Breakthrough GlycoMimetics is conducting a pivotal Phase 3 trial in the US, Europe and Australia to determine if its drug candidate, uproleselan, can successfully treat patients with relapsed and refractory acute myeloid leukemia (AML), a blood cancer. The unique aspect of uproleselan is […]
ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 29, 2019– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and […]
Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapySecond initiation among three late-stage uproleselan clinical trials ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 23, 2019– GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement […]
Rachel King has charted a unique career — from consultant to VC to startup to now CEO — and is leading a pioneering company in the use of glycobiology technology. Click here to listen to the podcast via Pharmavoice.com”
Rachel K. King, Co-Founder and CEO, GlycoMimetics, Inc. (GMI), joins Rich Bendis for the latest episode of BioTalk. They cover topics from her background in the industry to running a publicly traded company in the BioHealth Capital Region. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the […]
